BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, April 19, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Jan. 20, 2011
View Archived Issues
Phase II trial evaluates dutasteride in spinal and bulbar muscular atrophy / News in Context
Read More
Russian scientists claim new melanocortin MC2 receptor ligands
Read More
DA-1229 may be beneficial in diabetes types 1 and 2
Read More
Talactoferrin increases survival of patients with septic shock and systolic dysfunction
Read More
Ironwood Pharma and Protagonist Therapeutics join to develop new peptide therapeutics
Read More
MAb 1C11 impairs growth of S. aureus and may be candidate drug for MRSA-associated osteomyelitis
Read More
Therapure Biopharma describes hemoglobin-drug conjugates for targeted delivery to the liver
Read More
Zalicus provides update on product candidates and collaborations
Read More
Cadence Pharma launches Ofirmev in U.S. for pain and fever
Read More
Johns Hopkins Brain Science Institute and Ortho-McNeil-Janssen enter collaboration
Read More
New inhibitors claimed of Egl nine homolog 1, 2 and 3
Read More
Dainippon Sumitomo claims new dopamine D2 receptor ligands
Read More
New inhibitors of JAK1, JAK2 and JAK3 developed at Genentech
Read More
Targacept reports phase II data on TC-5619 in schizophrenia
Read More
Ono Pharmaceutical divulges new chymase inhibitors
Read More
DWTI identifies new substituted isoquinoline derivatives
Read More
UCB provides update on development milestones
Read More
Ono Pharma claims new agents for urinary incontinence
Read More
Alexza completes end-of-review meeting with FDA regarding AZ-004
Read More
GSK-2402968 enters phase III trial in Duchenne's muscular dystrophy
Read More
PROLOR and Yeda sign agreement for reversible PEGylation technology
Read More
Harbor BioSciences licenses three compounds to CIPI in China
Read More
Zanamivir enters phase III trial in hospitalized patients with influenza
Read More
FDA issues complete response letter to MannKind regarding Afrezza NDA
Read More
Lundbeck begins phase III program for zicronapine
Read More